Scientific Directorate, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe-University, Frankfurt, Germany.
Eur J Cancer. 2022 Sep;172:138-145. doi: 10.1016/j.ejca.2022.03.036. Epub 2022 Jun 27.
The frequency of Langerhans cell histiocytosis (LCH) and associated malignancies (AM) is greater than statistically expected. Here, we analyze LCH-AM co-occurrence in both children and adults.
Between 1991 and 2015, data were collected by regular questionnaires to members of the Histiocyte Society and searches in PubMed and Abstract Books. Patients were grouped by age at LCH diagnosis (≤ and >18 years), and types and timing of AM occurrence were plotted with respect to the LCH diagnosis. For the statistical analysis, only the first AM were considered.
A total of 285 LCH-AM in 270 patients were identified, 116 (43%) ≤ 18 years, and 154 (57%) >18 years. In childhood LCH-AM pairs, leukemias and myeloproliferative disorders (n = 58; 50.0%) prevailed over solid tumors (n = 43; 37.1%) and lymphoma (n = 15; 12.9%). In adults, solid tumors were reported in 61 patients (39.6%), lymphoma, and leukemias and myeloproliferative disorders in 56 (36.4%) and 37 (24.0%) patients, respectively. In most children, AM followed LCH (n = 69, 59.5%), whereas in adults, LCH and AM occurred concurrently in 69 patients (44.8%). In children, T-lineage acute lymphoblastic leukemia (ALL) and promyelocytic acute myeloid leukemia (AML) and retinoblastoma were over-represented and thyroid carcinoma in adults.
The largest collection of data on LCH-AM to date clearly indicates inherent relationships between specific types of AM and LCH, which may be due to therapy effects, clonal evolution, and germ-line predisposition, respectively. Prospective thorough genetic analysis is warranted and will hopefully shed light on the association of LCH and second neoplasms.
朗格汉斯细胞组织细胞增生症(LCH)和相关恶性肿瘤(AM)的发病率高于统计学预期。在这里,我们分析了儿童和成人中 LCH-AM 的同时发生。
在 1991 年至 2015 年期间,通过定期问卷调查收集组织细胞协会成员的数据,并在 PubMed 和摘要书籍中进行搜索。根据 LCH 诊断时的年龄(≤18 岁和>18 岁)将患者分组,并根据 LCH 诊断绘制 AM 发生的类型和时间。对于统计分析,仅考虑第一次 AM。
共确定了 270 例患者中的 285 例 LCH-AM,其中 116 例(43%)≤18 岁,154 例(57%)>18 岁。在儿童 LCH-AM 对中,白血病和骨髓增生性疾病(n=58;50.0%)多于实体瘤(n=43;37.1%)和淋巴瘤(n=15;12.9%)。在成年人中,61 例患者报告有实体瘤(39.6%),56 例和 37 例患者分别有淋巴瘤和白血病及骨髓增生性疾病(36.4%和 24.0%)。在大多数儿童中,AM 紧随 LCH 之后(n=69,59.5%),而在成年人中,69 例患者的 LCH 和 AM 同时发生(44.8%)。在儿童中,T 系急性淋巴细胞白血病(ALL)和早幼粒细胞性急性髓细胞性白血病(AML)和视网膜母细胞瘤较为常见,而在成年人中则为甲状腺癌。
迄今为止,关于 LCH-AM 的最大数据收集清楚地表明了特定类型的 AM 和 LCH 之间存在内在关系,这可能分别归因于治疗效果、克隆进化和种系易感性。需要进行前瞻性的全面遗传分析,希望这将有助于阐明 LCH 和第二肿瘤之间的关联。